13.17
肝病对药代动力学的影响：病理生理学评估与肝功能检查
在临床实践中，由于相关技术的复杂性和专业性，直接测量肝血流量以评估肝功能存在重大挑战。因此，医务人员通常依赖于全面的临床检查和肝功能检查所得出的经验性估计值来评估肝功能状况。在可供使用的工具中，Child–Pugh 和 MELD 评分系统因其能够对肝功能损害程度进行分级和评估而被广泛应用。然而，需要…
在临床实践中，由于需要特殊技术，直接测量肝脏血流量以评估肝功能往往不切实际。
相反，临床医生通过患者检查和肝功能检测来评估肝功能。
Child-Pugh 和 MELD 有助于评估肝功能损害，但不能直接反映药物的药代动力学特征。
慢性肝病会影响药物代谢和清除，因此在给药前需要进行个体化的风险评估。
对于肝功能损害患者的给药方案仍处于持续研究阶段。然而，诸如转氨酶、碱性磷酸酶、胆红素和凝血酶原时间等药物标志物可为肝功能提供有价值的参考信息。
例如，升高的AST/ALT比值提示急性肝损伤、酒精性肝炎或进展期肝纤维化，而碱性磷酸酶（AP）水平升高可能表明肝肿瘤或胆道梗阻。
此外，尿液中胆红素水平的异常和凝血酶原时间的改变可分别用于诊断肝胆疾病和肝功能衰竭。
View the full transcript and gain access to JoVE Core videos
Q1: Why can't clinicians directly measure hepatic blood flow to assess liver function?
Direct measurement of hepatic blood flow requires specialized techniques that are often impractical in clinical settings. Instead, clinicians estimate hepatic function through patient examination and liver function tests, which provide more accessible and reliable information for assessing drug metabolism and clearance in patients with liver disease.
Q2: What do the Child-Pugh and MELD scores tell us about drug pharmacokinetics?
While the Child-Pugh and MELD scoring systems effectively categorize hepatic impairment severity, they do not directly correlate with drug pharmacokinetics. These scores assess liver function but don't reliably predict how drugs will be metabolized or cleared in hepatically impaired patients, necessitating additional assessment for dosing decisions.
Q3: How do elevated AST and ALT ratios help diagnose liver disease?
Elevated AST/ALT ratios indicate acute liver injury, alcoholic hepatitis, or advanced liver fibrosis. These aminotransferase markers provide valuable insights into hepatic function and the liver's capacity to metabolize drugs, helping clinicians assess the degree of hepatic impairment and adjust medication dosing accordingly.
Q4: What does increased alkaline phosphatase suggest about liver health?
Increased alkaline phosphatase levels may indicate hepatic tumors or biliary obstruction, signaling potential compromise in liver function. This marker helps clinicians identify structural or metabolic abnormalities affecting the liver's ability to clear drugs and maintain functional capacity in patients requiring medication adjustments.
Q5: How do prothrombin time and urinary bilirubin levels differ in assessing hepatic disease?
Prothrombin time deviations signal hepatic failure or biliary obstruction by reflecting the liver's synthetic function, while variations in urinary bilirubin levels help diagnose hepatobiliary disease. Together, these markers provide complementary information about liver dysfunction and guide effect of hepatic disease on pharmacokinetics dose adjustments due to hepatic impairment.
Q6: Why does chronic liver disease require different dosing approaches than acute hepatitis?
Chronic liver disease significantly compromises drug metabolism and clearance, requiring systematic dosing adjustments. Acute hepatitis causes more nuanced metabolic changes, necessitating case-by-case assessment. Both conditions demand tailored risk evaluation before dosing, though establishing standardized guidelines for hepatically impaired patients remains an evolving area of clinical practice.
Q7: What role do liver function tests play in medication management for hepatic impairment?
Liver function tests measuring aminotransferases, alkaline phosphatase, bilirubin, and prothrombin time provide critical insights into hepatic function and drug clearance capacity. These markers enable clinicians to make informed decisions about tailored therapeutic interventions and medication adjustments, ensuring safe and effective treatment in patients with hepatic disease.